The pancreatic cancer cell lines with higher levels of CEACAM5 generated fewer ATPs when exposed to niclosamide, palmostatin, SB-225002, SGX-523, axitinib, SCH-79797, sorafenib and 3-CI-AHPC (Fig. 5A-H), which means that those inhibitors could efficiently target CEACAM5high pancreatic cancer cells. Here, CEACAM5 is linked to familial pancreatic carcinoma.